SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
Year: 2019
Type: article
Abstract: The authors hypothesized that despite similar cardiovascular event rates, the improved cardiovascular survival from sodium glucose transporter 2 (SGLT2) inhibition, seen clinically, could be via a direct cytoprotective effect, including protection against myocardial ischemia/reperfusion injury. Langendorff-perfused hearts, from diabetic and nondiabetic rats, fed long-term for 4 weeks with canagliflozin, had lower infarct sizes; this being the first demonstration of canagliflozin's cardioprotective effect against ischemia/reperfusion injury in both diabetic and nondiabetic animals. By contrast, direct treatment of isolated nondiabetic rat hearts with canagliflozin, solubilized in the isolated Langendorff perfusion buffer, had no impact on infarct size. This latter study demonstrates that the infarct-sparing effect of long-term treatment with canagliflozin results from either a glucose-independent effect or up-regulation of cardiac prosurvival pathways. These results further suggest that SGLT2 inhibitors could be repurposed as novel cardioprotective interventions in high-risk cardiovascular patients irrespective of diabetic status.
Authors: Ven G. Lim, Robert M. Bell, Sapna Arjun, Maria Kolatsi-Joannou, David A. Long, Derek M. Yellon
Institution: University College London
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,453
Funders: American Heart Association, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi, American College of Cardiology Foundation, Patient-Centered Outcomes Research Institute, Verily Life Sciences, AstraZeneca HealthCare Foundation, National Institute for Health and Care Research, British Heart Foundation, Kidney Research UK, Diabetes UK, University College London, Great Ormond Street Hospital for Children, Novo Nordisk, National Institutes of Health, Medical Research Council, Cilag
Awards: Using zebrafish to implicate novel genes in the early stages of diabetic kidney disease, G18730014, Investigating the renal microvasculature in polycystic kidney disease, Sodium/glucose transporters in the heart and their role in hyperglycaemic exacerbation of ischaemia/ reperfusion injury following acute myocardial infarction, Targeting kidney lymphatics in diabetic nephropathy
OpenAlex ID: W2913619273
